Cleared Traditional

K770015 - NOSECLIP FOR RESP. CARE & PULMON. FUNC. (FDA 510(k) Clearance)

Class I Anesthesiology device.

K770015 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1977
Decision
72d
Days
Class 1
Risk

K770015 is an FDA 510(k) clearance for the NOSECLIP FOR RESP. CARE & PULMON. FUNC.. Classified as Clip, Nose (product code BXJ), Class I - General Controls.

Submitted by Bd Becton Dickinson Vacutainer Systems Preanalytic (Washington, US). The FDA issued a Cleared decision on March 16, 1977 after a review of 72 days - a notably fast clearance cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.6225 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Bd Becton Dickinson Vacutainer Systems Preanalytic devices

Submission Details

510(k) Number K770015 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 03, 1977
Decision Date March 16, 1977
Days to Decision 72 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 139d · This submission: 72d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code BXJ Clip, Nose
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 868.6225
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.